XML 45 R35.htm IDEA: XBRL DOCUMENT
v3.24.2.u1

Revenue (Details) - USD ($) $ in Thousands | 3 Months Ended | 6 Months Ended |
--- | --- | --- | ---
Jun. 30, 2024 | Jul. 02, 2023 | Jun. 30, 2024 | Jul. 02, 2023 | Dec. 31, 2023
Disaggregation of Revenue [Line Items] |  |  |  |  |
Revenue from Contract with Customer, Excluding Assessed Tax | $ 691,685 | $ 709,066 | $ 1,341,605 | $ 1,383,931 |
Contract with Customer, Liability, Current | (20,369) |  | (20,369) |  | $ (22,504)
Contract with Customer, Asset, Net, Current | 50,413 |  | 50,413 |  | 52,648
Contract with Customer, Asset and Liability [Abstract] |  |  |  |  |
Contract with Customer, Asset, Net, Current | 50,413 |  | 50,413 |  | 52,648
Contract with Customer, Liability, Current | (20,369) |  | (20,369) |  | $ (22,504)
Americas [Member] |  |  |  |  |
Disaggregation of Revenue [Line Items] |  |  |  |  |
Revenue from Contract with Customer, Excluding Assessed Tax | 307,783 | 318,827 | 602,137 | 620,855 |
Europe [Member] |  |  |  |  |
Disaggregation of Revenue [Line Items] |  |  |  |  |
Revenue from Contract with Customer, Excluding Assessed Tax | 184,588 | 191,617 | 363,150 | 376,514 |
Asia [Member] |  |  |  |  |
Disaggregation of Revenue [Line Items] |  |  |  |  |
Revenue from Contract with Customer, Excluding Assessed Tax | 199,314 | 198,622 | 376,318 | 386,562 |
Diagnostics [Member] |  |  |  |  |
Disaggregation of Revenue [Line Items] |  |  |  |  |
Revenue from Contract with Customer, Excluding Assessed Tax | 377,838 | 372,713 | 724,721 | 719,137 |
Diagnostics [Member] | Americas [Member] |  |  |  |  |
Disaggregation of Revenue [Line Items] |  |  |  |  |
Revenue from Contract with Customer, Excluding Assessed Tax | 139,370 | 134,032 | 277,396 | 272,206 |
Diagnostics [Member] | Europe [Member] |  |  |  |  |
Disaggregation of Revenue [Line Items] |  |  |  |  |
Revenue from Contract with Customer, Excluding Assessed Tax | 117,230 | 116,910 | 226,147 | 221,522 |
Diagnostics [Member] | Asia [Member] |  |  |  |  |
Disaggregation of Revenue [Line Items] |  |  |  |  |
Revenue from Contract with Customer, Excluding Assessed Tax | 121,238 | 121,771 | 221,178 | 225,409 |
Life Sciences [Member] |  |  |  |  |
Disaggregation of Revenue [Line Items] |  |  |  |  |
Revenue from Contract with Customer, Excluding Assessed Tax | 313,847 | 336,353 | 616,884 | 664,794 |
Life Sciences [Member] | Americas [Member] |  |  |  |  |
Disaggregation of Revenue [Line Items] |  |  |  |  |
Revenue from Contract with Customer, Excluding Assessed Tax | 168,413 | 184,795 | 324,741 | 348,649 |
Life Sciences [Member] | Europe [Member] |  |  |  |  |
Disaggregation of Revenue [Line Items] |  |  |  |  |
Revenue from Contract with Customer, Excluding Assessed Tax | 67,358 | 74,707 | 137,003 | 154,992 |
Life Sciences [Member] | Asia [Member] |  |  |  |  |
Disaggregation of Revenue [Line Items] |  |  |  |  |
Revenue from Contract with Customer, Excluding Assessed Tax | 78,076 | 76,851 | 155,140 | 161,153 |
Life Sciences reagents [Member] |  |  |  |  |
Disaggregation of Revenue [Line Items] |  |  |  |  |
Revenue from Contract with Customer, Excluding Assessed Tax | 176,852 | 192,208 | 354,077 | 382,086 |
Life Sciences reagents [Member] | Diagnostics [Member] |  |  |  |  |
Disaggregation of Revenue [Line Items] |  |  |  |  |
Revenue from Contract with Customer, Excluding Assessed Tax | 0 | 0 | 0 | 0 |
Life Sciences reagents [Member] | Life Sciences [Member] |  |  |  |  |
Disaggregation of Revenue [Line Items] |  |  |  |  |
Revenue from Contract with Customer, Excluding Assessed Tax | 176,852 | 192,208 | 354,077 | 382,086 |
Life Sciences instruments [Member] |  |  |  |  |
Disaggregation of Revenue [Line Items] |  |  |  |  |
Revenue from Contract with Customer, Excluding Assessed Tax | 86,252 | 100,101 | 167,162 | 196,275 |
Life Sciences instruments [Member] | Diagnostics [Member] |  |  |  |  |
Disaggregation of Revenue [Line Items] |  |  |  |  |
Revenue from Contract with Customer, Excluding Assessed Tax | 0 | 0 | 0 | 0 |
Life Sciences instruments [Member] | Life Sciences [Member] |  |  |  |  |
Disaggregation of Revenue [Line Items] |  |  |  |  |
Revenue from Contract with Customer, Excluding Assessed Tax | 86,252 | 100,101 | 167,162 | 196,275 |
Life Sciences software [Member] |  |  |  |  |
Disaggregation of Revenue [Line Items] |  |  |  |  |
Revenue from Contract with Customer, Excluding Assessed Tax | 50,743 | 44,044 | 95,645 | 86,433 |
Life Sciences software [Member] | Diagnostics [Member] |  |  |  |  |
Disaggregation of Revenue [Line Items] |  |  |  |  |
Revenue from Contract with Customer, Excluding Assessed Tax | 0 | 0 | 0 | 0 |
Life Sciences software [Member] | Life Sciences [Member] |  |  |  |  |
Disaggregation of Revenue [Line Items] |  |  |  |  |
Revenue from Contract with Customer, Excluding Assessed Tax | 50,743 | 44,044 | 95,645 | 86,433 |
Reproductive health [Member] |  |  |  |  |
Disaggregation of Revenue [Line Items] |  |  |  |  |
Revenue from Contract with Customer, Excluding Assessed Tax | 129,175 | 128,621 | 253,050 | 250,742 |
Reproductive health [Member] | Diagnostics [Member] |  |  |  |  |
Disaggregation of Revenue [Line Items] |  |  |  |  |
Revenue from Contract with Customer, Excluding Assessed Tax | 129,175 | 128,621 | 253,050 | 250,742 |
Reproductive health [Member] | Life Sciences [Member] |  |  |  |  |
Disaggregation of Revenue [Line Items] |  |  |  |  |
Revenue from Contract with Customer, Excluding Assessed Tax | 0 | 0 | 0 | 0 |
Applied genomics [Member] |  |  |  |  |
Disaggregation of Revenue [Line Items] |  |  |  |  |
Revenue from Contract with Customer, Excluding Assessed Tax | 51,287 | 59,097 | 98,734 | 122,507 |
Applied genomics [Member] | Diagnostics [Member] |  |  |  |  |
Disaggregation of Revenue [Line Items] |  |  |  |  |
Revenue from Contract with Customer, Excluding Assessed Tax | 51,287 | 59,097 | 98,734 | 122,507 |
Applied genomics [Member] | Life Sciences [Member] |  |  |  |  |
Disaggregation of Revenue [Line Items] |  |  |  |  |
Revenue from Contract with Customer, Excluding Assessed Tax | 0 | 0 | 0 | 0 |
Immunodiagnostics [Member] |  |  |  |  |
Disaggregation of Revenue [Line Items] |  |  |  |  |
Revenue from Contract with Customer, Excluding Assessed Tax | 197,376 | 184,995 | 372,937 | 345,888 |
Immunodiagnostics [Member] | Diagnostics [Member] |  |  |  |  |
Disaggregation of Revenue [Line Items] |  |  |  |  |
Revenue from Contract with Customer, Excluding Assessed Tax | 197,376 | 184,995 | 372,937 | 345,888 |
Immunodiagnostics [Member] | Life Sciences [Member] |  |  |  |  |
Disaggregation of Revenue [Line Items] |  |  |  |  |
Revenue from Contract with Customer, Excluding Assessed Tax | $ 0 | $ 0 | $ 0 | $ 0 |

X
- References No definition available. + Details
Name: | us-gaap_ContractWithCustomerAssetAndLiabilityAbstract
Namespace Prefix: | us-gaap_
Data Type: | xbrli:stringItemType
Balance Type: | na
Period Type: | duration

X
- Definition Amount, after allowance for credit loss, of right to consideration in exchange for good or service transferred to customer when right is conditioned on something other than passage of time, classified as current. + References Reference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 606 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 3 -Publisher FASB -URI https://asc.fasb.org/1943274/2147479837/606-10-45-3 Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 606 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 1 -Publisher FASB -URI https://asc.fasb.org/1943274/2147479837/606-10-45-1 Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 606 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 8 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479806/606-10-50-8 + Details
Name: | us-gaap_ContractWithCustomerAssetNetCurrent
Namespace Prefix: | us-gaap_
Data Type: | xbrli:monetaryItemType
Balance Type: | debit
Period Type: | instant

X
- Definition Amount of obligation to transfer good or service to customer for which consideration has been received or is receivable, classified as current. + References Reference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 606 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 1 -Publisher FASB -URI https://asc.fasb.org/1943274/2147479837/606-10-45-1 Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 606 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 8 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479806/606-10-50-8 Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 606 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 2 -Publisher FASB -URI https://asc.fasb.org/1943274/2147479837/606-10-45-2 + Details
Name: | us-gaap_ContractWithCustomerLiabilityCurrent
Namespace Prefix: | us-gaap_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | instant

X
- Definition Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table. + References Reference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 606 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 5 -Publisher FASB -URI https://asc.fasb.org/1943274/2147479806/606-10-50-5 Reference 2: http://www.xbrl.org/2003/role/exampleRef -Topic 606 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 91 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479777/606-10-55-91 Reference 3: http://www.xbrl.org/2003/role/exampleRef -Topic 606 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 91 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479777/606-10-55-91 Reference 4: http://www.xbrl.org/2003/role/exampleRef -Topic 606 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 91 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479777/606-10-55-91 Reference 5: http://www.xbrl.org/2003/role/exampleRef -Topic 606 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 91 -Subparagraph (d) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479777/606-10-55-91 Reference 6: http://www.xbrl.org/2003/role/exampleRef -Topic 606 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 91 -Subparagraph (e) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479777/606-10-55-91 Reference 7: http://www.xbrl.org/2003/role/exampleRef -Topic 606 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 91 -Subparagraph (f) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479777/606-10-55-91 Reference 8: http://www.xbrl.org/2003/role/exampleRef -Topic 606 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 91 -Subparagraph (g) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479777/606-10-55-91 + Details
Name: | us-gaap_DisaggregationOfRevenueLineItems
Namespace Prefix: | us-gaap_
Data Type: | xbrli:stringItemType
Balance Type: | na
Period Type: | duration

X
- Definition Amount, excluding tax collected from customer, of revenue from satisfaction of performance obligation by transferring promised good or service to customer. Tax collected from customer is tax assessed by governmental authority that is both imposed on and concurrent with specific revenue-producing transaction, including, but not limited to, sales, use, value added and excise. + References Reference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 41 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-41 Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 270 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (i) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482964/270-10-50-1 Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 32 -Subparagraph (ee) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32 Reference 4: http://fasb.org/us-gaap/role/ref/otherTransitionRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 32 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32 Reference 5: http://fasb.org/us-gaap/role/ref/otherTransitionRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 32 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32 Reference 6: http://www.xbrl.org/2003/role/disclosureRef -Topic 924 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SAB Topic 11.L) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479941/924-10-S99-1 Reference 7: http://www.xbrl.org/2003/role/disclosureRef -Topic 606 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 5 -Publisher FASB -URI https://asc.fasb.org/1943274/2147479806/606-10-50-5 Reference 8: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 30 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-30 Reference 9: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 42 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-42 Reference 10: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 22 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22 Reference 11: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 40 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-40 Reference 12: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 22 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22 Reference 13: http://www.xbrl.org/2003/role/disclosureRef -Topic 606 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 4 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479806/606-10-50-4 + Details
Name: | us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax
Namespace Prefix: | us-gaap_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | duration

X
- Details
Name: | srt_StatementGeographicalAxis=srt_AmericasMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_StatementGeographicalAxis=srt_EuropeMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_StatementGeographicalAxis=srt_AsiaMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_StatementBusinessSegmentsAxis=pki_DiagnosticsMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_StatementBusinessSegmentsAxis=pki_LifeSciencesMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | pki_MajorGoodsserviceLinesAxis=pki_LifeSciencesReagentsMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | pki_MajorGoodsserviceLinesAxis=pki_LifeSciencesInstrumentsMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | pki_MajorGoodsserviceLinesAxis=pki_LifeSciencesSoftwareMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | pki_MajorGoodsserviceLinesAxis=pki_ReproductiveHealthMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | pki_MajorGoodsserviceLinesAxis=pki_AppliedGenomicsMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | pki_MajorGoodsserviceLinesAxis=pki_ImmunodiagnosticsMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |